The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster

INTRODUCTION: A global vaccination program was implemented in late 2020 to end the pandemic caused by the SARS-CoV-2 virus. However, the immune response elicited by the vaccines proved to be insufficient due to the rapid emergence of new viral mutations. Therefore, the factors influencing cellular a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolszczak Biedrzycka, Blanka, Bieńkowska, Anna, Smolińska-Fijołek, Elwira, Biedrzycki, Grzegorz, Dorf, Justyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807069/
https://www.ncbi.nlm.nih.gov/pubmed/36600955
http://dx.doi.org/10.2147/IDR.S390351
_version_ 1784862638168080384
author Wolszczak Biedrzycka, Blanka
Bieńkowska, Anna
Smolińska-Fijołek, Elwira
Biedrzycki, Grzegorz
Dorf, Justyna
author_facet Wolszczak Biedrzycka, Blanka
Bieńkowska, Anna
Smolińska-Fijołek, Elwira
Biedrzycki, Grzegorz
Dorf, Justyna
author_sort Wolszczak Biedrzycka, Blanka
collection PubMed
description INTRODUCTION: A global vaccination program was implemented in late 2020 to end the pandemic caused by the SARS-CoV-2 virus. However, the immune response elicited by the vaccines proved to be insufficient due to the rapid emergence of new viral mutations. Therefore, the factors influencing cellular and humoral immune responses after the administration of different vaccines against SARS-CoV2 need to be identified. MATERIALS: In the present study, anti-SARS-CoV-2 antibody titers were analyzed 20 to 50 days after the administration of a third (booster) dose of the BNT162b2 vaccine in 192 residents of the city of Olsztyn (Poland) primed with two AstraZeneca or Pfizer/BioNTech vaccines. METHODS: Antibody titers were determined in venous blood serum in the ECLIA test using the Cobas e411 Roche analyzer. RESULTS: The study revealed that persons who received three doses of the Pfizer/BioNTech vaccine had significantly higher antibody titers than those who received two doses of AstraZeneca and a booster dose of Pfizer/BioNTech.
format Online
Article
Text
id pubmed-9807069
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-98070692023-01-03 The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster Wolszczak Biedrzycka, Blanka Bieńkowska, Anna Smolińska-Fijołek, Elwira Biedrzycki, Grzegorz Dorf, Justyna Infect Drug Resist Original Research INTRODUCTION: A global vaccination program was implemented in late 2020 to end the pandemic caused by the SARS-CoV-2 virus. However, the immune response elicited by the vaccines proved to be insufficient due to the rapid emergence of new viral mutations. Therefore, the factors influencing cellular and humoral immune responses after the administration of different vaccines against SARS-CoV2 need to be identified. MATERIALS: In the present study, anti-SARS-CoV-2 antibody titers were analyzed 20 to 50 days after the administration of a third (booster) dose of the BNT162b2 vaccine in 192 residents of the city of Olsztyn (Poland) primed with two AstraZeneca or Pfizer/BioNTech vaccines. METHODS: Antibody titers were determined in venous blood serum in the ECLIA test using the Cobas e411 Roche analyzer. RESULTS: The study revealed that persons who received three doses of the Pfizer/BioNTech vaccine had significantly higher antibody titers than those who received two doses of AstraZeneca and a booster dose of Pfizer/BioNTech. Dove 2022-12-29 /pmc/articles/PMC9807069/ /pubmed/36600955 http://dx.doi.org/10.2147/IDR.S390351 Text en © 2022 Wolszczak Biedrzycka et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wolszczak Biedrzycka, Blanka
Bieńkowska, Anna
Smolińska-Fijołek, Elwira
Biedrzycki, Grzegorz
Dorf, Justyna
The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster
title The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster
title_full The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster
title_fullStr The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster
title_full_unstemmed The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster
title_short The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster
title_sort influence of two priming doses of different anti-covid-19 vaccines on the production of anti-sars-cov-2 antibodies after the administration of the pfizer/biontech booster
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807069/
https://www.ncbi.nlm.nih.gov/pubmed/36600955
http://dx.doi.org/10.2147/IDR.S390351
work_keys_str_mv AT wolszczakbiedrzyckablanka theinfluenceoftwoprimingdosesofdifferentanticovid19vaccinesontheproductionofantisarscov2antibodiesaftertheadministrationofthepfizerbiontechbooster
AT bienkowskaanna theinfluenceoftwoprimingdosesofdifferentanticovid19vaccinesontheproductionofantisarscov2antibodiesaftertheadministrationofthepfizerbiontechbooster
AT smolinskafijołekelwira theinfluenceoftwoprimingdosesofdifferentanticovid19vaccinesontheproductionofantisarscov2antibodiesaftertheadministrationofthepfizerbiontechbooster
AT biedrzyckigrzegorz theinfluenceoftwoprimingdosesofdifferentanticovid19vaccinesontheproductionofantisarscov2antibodiesaftertheadministrationofthepfizerbiontechbooster
AT dorfjustyna theinfluenceoftwoprimingdosesofdifferentanticovid19vaccinesontheproductionofantisarscov2antibodiesaftertheadministrationofthepfizerbiontechbooster
AT wolszczakbiedrzyckablanka influenceoftwoprimingdosesofdifferentanticovid19vaccinesontheproductionofantisarscov2antibodiesaftertheadministrationofthepfizerbiontechbooster
AT bienkowskaanna influenceoftwoprimingdosesofdifferentanticovid19vaccinesontheproductionofantisarscov2antibodiesaftertheadministrationofthepfizerbiontechbooster
AT smolinskafijołekelwira influenceoftwoprimingdosesofdifferentanticovid19vaccinesontheproductionofantisarscov2antibodiesaftertheadministrationofthepfizerbiontechbooster
AT biedrzyckigrzegorz influenceoftwoprimingdosesofdifferentanticovid19vaccinesontheproductionofantisarscov2antibodiesaftertheadministrationofthepfizerbiontechbooster
AT dorfjustyna influenceoftwoprimingdosesofdifferentanticovid19vaccinesontheproductionofantisarscov2antibodiesaftertheadministrationofthepfizerbiontechbooster

Ejemplares similares